Stefano Casarin

Assistant Professor

Houston Methodist
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Bone metastasis (BM) is a leading cause of morbidity and mortality in patients with prostate and renal cancer. The complex and dynamic biological processes driving its progression present significant challenges for both understanding and treating this disease. Although current in vivo research provides valuable insights, it is often limited by the inability to fully capture the intricate and multifactorial nature of BM. Thus, complementing existing in vivo models with multiscale computational approaches is crucial for dissecting the complex interactions between tumor cells and the bone microenvironment to advance our understanding of the metastatic process and therapy response. Accordingly, we developed a series of in vivo -inspired, spatially explicit, multicellular agent-based models of BM that effectively recapitulate key aspects of tumor progression, including angiogenesis and bone resorption. The digital twins were rigorously calibrated using in vivo data from prostate and kidney tumors. The models have utility for evaluating therapy response, as verified by the simulation of both the antiangiogenic effects of cabozantinib and the antiresorptive effects of zoledronic acid. These results highlight the predictive character of the agent-based models of BM in anticipating therapeutic outcomes and increasing our understanding of the complex dynamics of BM. Significance: The model offers a transformative tool for evaluating treatment strategies, including combination therapies, with the potential to accelerate the development of highly effective, targeted interventions for bone metastatic cancers. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

Year:

2025

Adoptive cell therapies (ACT) leverage tumor-immune interactions to cure cancer. Despite promising phase I/II clinical trials of chimeric-antigen-receptor natural killer (CAR-NK) cell therapies, molecular mechanisms and cellular properties required to achieve clinical benefits in broad cancer spectra remain underexplored. While in vitro and in vivo experiments are required in this endeavor, they are typically expensive, laborious, and limited to targeted investigations. Here, we present ABMACT (Agent-Based Model for Adoptive Cell Therapy), an in silico approach employing agent-based models (ABM) to simulate the continuous course and dynamics of an evolving tumor-immune ecosystem, consisting of heterogeneous “virtual cells” created based on knowledge and omics data observed in experiments and patients. Applying ABMACT in multiple therapeutic context indicates that to achieve optimal ACT efficacy, it is key to enhance immune cellular proliferation, cytotoxicity, and serial killing capacity. With ABMACT, in silico trials can be performed systematically to inform ACT product development and predict optimal treatment strategies.

Year:

2025

Year:

2023

Collaborators (6)

Pietro Cerveri

Full Professor of Bioengineering

University of Pavia

ITALY
View details

Katayoun Rezvani

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eleonora Dondossola

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rafet Basar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

May Daher

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details